Uroepithelial and kidney carcinoma in Lynch syndrome

Familial Cancer

Volumn 11, Issue 3, 2012, Pages 395-401

  Aarnio, Markku ^a   Säily, Matti ^b   Juhola, Matti ^a   Gylling, Annette ^c   Peltomäki, Päivi ^c   Järvinen, Heikki J ^b   Mecklin, Jukka Pekka ^a  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

HNPCC; Lynch syndrome; Surveillance; Urological tumors

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CYSTECTOMY; FEMALE; FOLLOW UP; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; KIDNEY CANCER; MALE; NEPHROURETERECTOMY; PRIORITY JOURNAL; URETER CANCER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGE OF ONSET; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA-BINDING PROTEINS; FEMALE; FINLAND; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84870420051     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-012-9526-6     Document Type: Article

References (30)

1. Abdel-Rahman WM, Mecklin JP, Peltomaki P (2006) The genetics of HNPCC: application to diagnosis and screening. Crit Rev Oncol Hematol 58:208-220
2. Peltomäki P, Vasen H (2004) Mutations associated with HNPCC predisposition - update of ICG-HNPCC/InSiGHT mutation database. Dis Markers 20:269-276
3. Holmberg M, Kristo P, Chadwick RB et al. (1998)Mutation sharing, predominant involvement of theMLH1 gene, and description of four novel mutations in hereditary nonpolyposis colorectal cancer. Mutation in brief#144 (Online). Hum Mut 11:482
4. Lynch HT, Smyrk T (1996) Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 78:1149-1167
5. Watson P, Vasen HFA, Mecklin JP et al (2008) The risk of extracolonic, extra-endometrial cancer in the Lynch syndrome. In J Cancer 123:444-449
6. Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch repair genes. Int J Cancer 81:214-218
7. Vasen HFA, Stormorken A, Menko FM et al (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: A study of hereditary nonpolyposis colorectal cancer studies. J Clin Oncol 19:4074-4080
8. Peltomäki P (2003) Role of DNA mismatch repair genes in the pathogenesis of human cancer. J Clin Oncol 21:1174-1179
9. Gylling AHS, Nieminen TT, Abdel-Rahman WM et al (2008) Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tumors. Carcinogenesis 29:1351-1359
10. Vasen HFA, Möslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44:353-362
11. Vasen HF, Wijnen JT, Menko FH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020-1027
12. Van der Post RS, Kiemeney LA, Ligtenberg MJL et al (2010) Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 47:464-470
13. Finnish Cancer Registry, Helsinki, Finland (2011) The mean ages and relative survival rates (%) of patients in the general population were calculated directly from the original data of the Finnish cancer Registry. www.cancerregistry.fi
14. Roupret M, Yates DR, Comperat E, Cussenot O (2008) Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 54:581-592
15. Vasen HFA, Mecklin J-P, Khan PM, Lynch HT (1991) The international collaborative group on hereditary nonpolyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34:424-425
16. Vasen HFA, Watson P, Mecklin J-P, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453-1456
17. Sijmons RH, Kiemeney LALM, Witjes JA, Vasen HFA (1998) Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol 160:466-470
18. Acher P, Kiela G, Thomas K, O'Brien T (2010) Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. BJU 106(3):300-302
19. Grossman HB, Messig E, Soloway M et al (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293:810-816
20. Koonstra JJ, Mourits MJ, Sijmons RH, Leviveld AM, Hollema H, Kleibeuker JH (2009) Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 10:400-408
21. Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM (2003) Hereditary renal cancers. Radiology 1:33-46
22. Zachau P, Walter S (2011) Urinary tract cancer in patients with hereditary non-polyposis colorectal cancer. Scand J Urol Nephr Early Online 1-3
23. Helenon O, Correas JM, Balleyguier C, Ghouadni M, Cornud F (2001) Ultrasound of renal tumors. Eur Radiol 11:1890-1901
24. Siemer S, Uder U et al (2000) Value of ultrasound in early diagnosis of renal cell carcinomas. Urologe 39:149-153
25. Mostbeck GH, Zontsich T, Turetschek K (2001) Ultrasound of the kidney: obstruction and medical disease. Eur Radiol 11:1878-1889
26. Jamis-Dow CA, Choyke PL, Jennings SB et al (1996) Small (
27. Bastacky S, Ibrahim S, Wilczynski SP, Murphy VM (1999) The accuracy of urinary cytology in daily practice. Cancer 87(3):118-128
28. Konety RB, Getzenberg RH (2001) Urine based markers of urology malignancies. J Urol 165:600-611
29. Myrhoj T, Andersen MB, Bernstein I (2008) Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Fam Cancer 7:303-307
30. Van Rhijn BGW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47(6):736-748